Clinical evaluation of efficacy and safety of nateglinide in the treatment of type 2 diabetes.
- Author:
Yu-Xiu LI
1
;
Guo-Xian DING
;
Qi-Fu LI
;
Li CHEN
;
Guo-Liang HU
;
Qiu-He JI
;
Shou-Jun WANG
;
Yan GUO
;
Rong LUO
;
Wei-Kai HOU
;
Pu-Neng WANG
;
Nan-Yan ZHANG
;
Ya-Ping ZHANG
;
Heng WANG
Author Information
- Publication Type:Journal Article
- MeSH: Blood Glucose; drug effects; Cyclohexanes; administration & dosage; adverse effects; therapeutic use; Diabetes Mellitus, Type 2; drug therapy; Drug Administration Schedule; Female; Humans; Hypoglycemic Agents; administration & dosage; adverse effects; therapeutic use; Male; Middle Aged; Phenylalanine; administration & dosage; adverse effects; analogs & derivatives; therapeutic use; Treatment Outcome
- From: Acta Academiae Medicinae Sinicae 2008;30(2):211-213
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the efficacy and safety of nateglinide, a new antidiabetic agent, in the treatment of type 2 diabetes.
METHODSA total of 219 treatment-naïve patients with type 2 diabetes from 6 centers were enrolled in this study and blindly divided into nateglinide group (n = 105) and repaglinide group (n = 114). In all patients, the disease was confirmed for at least three months. The whole observation lasted for 12 weeks. The efficacy indicators measured include glycohemoglobin A1c (HbA1c), fasting blood glucose, and 2 hours postprandial blood glucose, and the safety parameters measured included renal and hepatic function, serum lipids, and blood and urea profiles.
RESULTSSimilar decreases in fasting blood glucose, 2 hours postprandial blood glucose, and HbA1 c were found in both nateglinide group and repaglinide group without significant differences. No severe adverse events were noted. The hypoglycemia event reports were not significantly different between these two groups.
CONCLUSIONNateglinide is an effective and safe drug in treating type 2 diabetes.